Cargando…

Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C

BACKGROUND: In January 2015, the first interferon-free direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection was approved for inclusion in Israel’s national basket of health services. During 2015, HCV genotype 1 patients with advanced liver fibrosis (stage F3-F4) were e...

Descripción completa

Detalles Bibliográficos
Autores principales: Avisar, Nitzan, Heller, Yael, Weil, Clara, Ben-Baruch, Aviva, Potesman-Yona, Shani, Oren, Ran, Chodick, Gabriel, Shalev, Varda, Ash, Nachman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618729/
https://www.ncbi.nlm.nih.gov/pubmed/28954630
http://dx.doi.org/10.1186/s13584-017-0172-1
_version_ 1783267252111409152
author Avisar, Nitzan
Heller, Yael
Weil, Clara
Ben-Baruch, Aviva
Potesman-Yona, Shani
Oren, Ran
Chodick, Gabriel
Shalev, Varda
Ash, Nachman
author_facet Avisar, Nitzan
Heller, Yael
Weil, Clara
Ben-Baruch, Aviva
Potesman-Yona, Shani
Oren, Ran
Chodick, Gabriel
Shalev, Varda
Ash, Nachman
author_sort Avisar, Nitzan
collection PubMed
description BACKGROUND: In January 2015, the first interferon-free direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection was approved for inclusion in Israel’s national basket of health services. During 2015, HCV genotype 1 patients with advanced liver fibrosis (stage F3-F4) were eligible for treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir (OMB/PTV/r + DSV) provided through the four national health plans. As all health plans committed to identifying eligible patients nationwide, risk-sharing agreements created an additional incentive to develop an innovative model for rapid treatment delivery. AIM: This article aims to describe the development and implementation of a multi-disciplinary patient-centered model for the expedited provision of costly therapies in a community setting, based on experience delivering new HCV therapy in 2015. METHODS: We present the case of the Central District in Maccabi Healthcare Services (MHS), one of five districts in a 2-million-member healthcare provider. We describe the dimensions of the model and its implementation, including the composition and responsibilities of the multi-disciplinary team, screening for patient eligibility, provision of care, and barriers and facilitators identified at each stage. RESULTS: The experience of the MHS Central District indicates that good communication between all stakeholders was the key driver of successful implementation of the model. Overall, monthly treatment uptake increased following the intervention and by the end of 2015 a total of 99 patients were treated with OMB/PTV/r + DSV in this district. Early data indicate high effectiveness in this population and evaluation in ongoing. CONCLUSIONS: This multi-disciplinary patient-centered model enabled rapid integration of screening and disease staging to identify and treat eligible HCV patients in the MHS central district. The model forms the basis of the 2017 project to deliver DAAs according to broader health basket criteria and may be adapted for the provision of other innovative health technologies in different healthcare settings.
format Online
Article
Text
id pubmed-5618729
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56187292017-10-03 Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C Avisar, Nitzan Heller, Yael Weil, Clara Ben-Baruch, Aviva Potesman-Yona, Shani Oren, Ran Chodick, Gabriel Shalev, Varda Ash, Nachman Isr J Health Policy Res Integrative Article BACKGROUND: In January 2015, the first interferon-free direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection was approved for inclusion in Israel’s national basket of health services. During 2015, HCV genotype 1 patients with advanced liver fibrosis (stage F3-F4) were eligible for treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir (OMB/PTV/r + DSV) provided through the four national health plans. As all health plans committed to identifying eligible patients nationwide, risk-sharing agreements created an additional incentive to develop an innovative model for rapid treatment delivery. AIM: This article aims to describe the development and implementation of a multi-disciplinary patient-centered model for the expedited provision of costly therapies in a community setting, based on experience delivering new HCV therapy in 2015. METHODS: We present the case of the Central District in Maccabi Healthcare Services (MHS), one of five districts in a 2-million-member healthcare provider. We describe the dimensions of the model and its implementation, including the composition and responsibilities of the multi-disciplinary team, screening for patient eligibility, provision of care, and barriers and facilitators identified at each stage. RESULTS: The experience of the MHS Central District indicates that good communication between all stakeholders was the key driver of successful implementation of the model. Overall, monthly treatment uptake increased following the intervention and by the end of 2015 a total of 99 patients were treated with OMB/PTV/r + DSV in this district. Early data indicate high effectiveness in this population and evaluation in ongoing. CONCLUSIONS: This multi-disciplinary patient-centered model enabled rapid integration of screening and disease staging to identify and treat eligible HCV patients in the MHS central district. The model forms the basis of the 2017 project to deliver DAAs according to broader health basket criteria and may be adapted for the provision of other innovative health technologies in different healthcare settings. BioMed Central 2017-09-28 /pmc/articles/PMC5618729/ /pubmed/28954630 http://dx.doi.org/10.1186/s13584-017-0172-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Integrative Article
Avisar, Nitzan
Heller, Yael
Weil, Clara
Ben-Baruch, Aviva
Potesman-Yona, Shani
Oren, Ran
Chodick, Gabriel
Shalev, Varda
Ash, Nachman
Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C
title Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C
title_full Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C
title_fullStr Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C
title_full_unstemmed Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C
title_short Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C
title_sort multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis c
topic Integrative Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618729/
https://www.ncbi.nlm.nih.gov/pubmed/28954630
http://dx.doi.org/10.1186/s13584-017-0172-1
work_keys_str_mv AT avisarnitzan multidisciplinarypatientcenteredmodelfortheexpeditedprovisionofcostlytherapiesincommunitysettingsthecaseofnewmedicationforhepatitisc
AT helleryael multidisciplinarypatientcenteredmodelfortheexpeditedprovisionofcostlytherapiesincommunitysettingsthecaseofnewmedicationforhepatitisc
AT weilclara multidisciplinarypatientcenteredmodelfortheexpeditedprovisionofcostlytherapiesincommunitysettingsthecaseofnewmedicationforhepatitisc
AT benbaruchaviva multidisciplinarypatientcenteredmodelfortheexpeditedprovisionofcostlytherapiesincommunitysettingsthecaseofnewmedicationforhepatitisc
AT potesmanyonashani multidisciplinarypatientcenteredmodelfortheexpeditedprovisionofcostlytherapiesincommunitysettingsthecaseofnewmedicationforhepatitisc
AT orenran multidisciplinarypatientcenteredmodelfortheexpeditedprovisionofcostlytherapiesincommunitysettingsthecaseofnewmedicationforhepatitisc
AT chodickgabriel multidisciplinarypatientcenteredmodelfortheexpeditedprovisionofcostlytherapiesincommunitysettingsthecaseofnewmedicationforhepatitisc
AT shalevvarda multidisciplinarypatientcenteredmodelfortheexpeditedprovisionofcostlytherapiesincommunitysettingsthecaseofnewmedicationforhepatitisc
AT ashnachman multidisciplinarypatientcenteredmodelfortheexpeditedprovisionofcostlytherapiesincommunitysettingsthecaseofnewmedicationforhepatitisc